Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the effect of orlistat with and without levocarnitine on insulin resistance in obese patients with type 2 diabetes mellitus inadequately controlled with insulin or oral antihyperglycaemics.

Next Previous
Trial Profile

Comparison of the effect of orlistat with and without levocarnitine on insulin resistance in obese patients with type 2 diabetes mellitus inadequately controlled with insulin or oral antihyperglycaemics.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levocarnitine (Primary) ; Orlistat (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics

Most Recent Events

  • 01 Oct 2011 Results published in Fundamental and Clinical Pharmacology.
  • 12 Jan 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top